Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

Annals of Clinical Biochemistry

Volumn 40, Issue 1, 2003, Pages 25-40

  Verbeek, M M ^a,b   De Jong, D ^a   Kremer, H P H ^a  

^a 319 LKN ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; BRAIN PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; NEURON SPECIFIC ENOLASE; NEURONAL THREAD PROTEIN; PROTEIN; PROTEIN S100B; TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; ALPHA SYNUCLEINOPATHY; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; GENETICS; HUMAN; METABOLIC DISORDER; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; VALIDATION PROCESS;

ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BRAIN; CALCIUM-BINDING PROTEINS; CREUTZFELDT-JAKOB SYNDROME; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; LITHOSTATHINE; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROFILAMENT PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PHOSPHORYLATION; S100 PROTEINS; SYNUCLEINS; TAU PROTEINS;

EID: 0037225726     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303321016141     Document Type: Review

References (121)

1. Lee VMY, Balin BJ, Otvos L, Trojanowski JQ. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991; 251: 675-8
2. Iqbal K, Grundke-Iqbal I. Neurofibrillary tangles. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia: WB Saunders Co, 1994: 71-81
3. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann N Y Acad Sci 1996; 777: 121-31
4. Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, et al. From genetics to pathology: Tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc Lond B Biol Sci 2001; 356: 213-27
5. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, et al. Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 1996; 777: 96-106
6. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993; 10: 1089-99
7. Lovestone S, Reynolds CH. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997; 78: 309-24
8. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl) 2002; 103: 26-35
9. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90
10. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992; 258: 126-9
11. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 1992; 359: 325-7
12. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-7
13. van Gool WA, Kuiper MA, Walstra GJ, Wolters EC, Bolhuis PA. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 37: 277-9
14. Southwick PC, Yamagata SK, Echofs CLJ, Higson GJ, Neynaber SA, Parson RE, et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996; 66: 259-65
15. Motter R, Vigo PC, Kholodenko D, Barbour R, Johnson WK, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38: 643-8
16. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993; 61: 1965-8
17. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996; 271: 22908-14
18. Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997; 148: 41-5
19. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: Differences between early- and late-onset alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-80
20. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000; 57: 100-5
21. Tapiola T, Pirttila T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000; 21: 735-40
22. Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 2000; 280: 119-22
23. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta 1-40, and A beta 1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol 1998; 44: 17-26
24. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De-Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 1999; 52: 1555-62
25. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 373-9
26. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998; 4: 832-4
27. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828-34
28. Hampel H, Teipel SJ, Padberg F, Haslinger A, Riemenschneider M, Schwarz MJ, et al. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. Brain Res 1999; 823: 104-12
29. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, et al. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995; 38: 649-52
30. Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 2000; 54: 1498-504
31. Franciotta D, Di Paolo E, Tinelli C, d'Eril GM. Protein tau in cerebrospinal fluid of patients with Alzheimer disease. Clin Chem 1998; 44: 357-8
32. Molina L, Touchon J, Herpe M, Lefranc D, Duplan L, Cristol JP, et al. Tau and apo E in CSF: Potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport 1999; 10; 3491-5
33. Rosler N, Wichart I, Bancher C, Jellinger KA. Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non Alzheimer's dementia? J Neural Transm Suppl 1996; 47: 259-66
34. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231-45
35. Hock C, Golombowski S, Naser W, Muller-Spahn F. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - Correlation with degree of cognitive impairment. Ann Neurol 1995; 37: 414-5
36. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995; 59: 280-3
37. Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995; 45: 788-93
38. Munroe WA, Southwick PC, Chang L, Scharre DW, Echols CLJ, Fu PC, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 1995; 25: 207-17
39. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999; 53: 1488-94
40. Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem 1997; 68: 430-3
41. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, et al. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5-8
42. Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 1622-8
43. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. Clinicopathologic correlates in Alzheimer disease: Assessment of clinical and pathological diagnostic criteria. Alzheimer Dis Assoc Disord 1993; 7: 152-64
44. Larson EB, Edwards JK, O'Meara E, Nochlin D, Sumi SM. Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J Gerontol A Biol Sci Med Sci 1996; 51: M313-8
45. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994; 51: 1198-204
46. Clark CM, Ewbank DC, Peskind E, Galasko D, Morris CS, McKeel D, et al. How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses? Neurobiol Aging 2002; 23 (Suppl 1): S274
47. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem 2001; 47: 1776-81
48. Kunicki S, Richardson J, Mehta PD, Kim KS, Zorychta E. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (Abeta)40, Abeta42, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin Biochem 1998; 31: 409-15
49. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Cerebrospinal fluid tau levels increase with age in healthy individuals. Dement Geriatr Cogn Disord 2001; 12: 127-32
50. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 1999; 46: 750-5
51. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997; 8: 3961-3
52. Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995; 37: 512-8
53. Sjogren M, Minthon L, Davidsson P, Granerus A-K, Clarberg A, Vanderstichele H, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563-79
54. Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960-4
55. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-30
56. Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, et al. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 1999; 52: 547-51
57. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937-45
58. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405
59. Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997; 48: 632-5
60. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996; 212: 209-11
61. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001; 172: 433-6
62. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand S, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697-9
63. Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1983; 3: 310-5
64. Saunders AM, Strittmatter WJ, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-72
65. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: High-avidity binding to βamyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-81
66. Henderson AS, Easteal S, Jorm AF, MacKinnon AJ, Korten AE, Christensen H, et al. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995; 346: 1387-90
67. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3
68. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell JPC, et al. Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease. Nature Genet 1994; 7: 180-3
69. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, et al. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 1999; 267: 65-8
70. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett 1996; 214: 163-6
71. Fabre SF, Forsell C, Viitanen M, Sjogren M, Wallin A, Blennow K, et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Exp Neurol 2001; 168: 413-8
72. Lemstra AW, van Meegen MT, Vreyling JP, Meijerink PH, Jansen GH, Bulk S. 14-3-3 Testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients. Neurology 2000; 55: 514-6
73. Collins S, Boyd A, Fletcher A, Gonzales M, McLean CA, Byron K, et al. Creutzfeldt-Jakob disease: Diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci 2000; 7: 203-8
74. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996; 335: 924-30
75. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro C, Knight RS, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55: 811-5
76. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58: 192-7
77. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2001; 71: 401-3
78. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, et al. Decreased beta-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000; 54: 1099-102
79. Urakami K, Wada K, Arai H, Sasaki H, Kanai M, Shoji M, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001; 183: 95-8
80. Mitani K, Furiya Y, Uchihara T, Ishii K, Yamanouchi H, Mizusawa H, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol 1998; 245: 44-6
81. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001; 50: 150-6
82. Jansen SE, Vermes I, de Vos RA. Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. Lancet 1998; 351: 1105-6
83. Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, Orti-Pareja M, Berbel A, Tallon-Barranco A, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett 1997; 238: 139-41
84. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000; 54: 1875-6
85. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000; 287: 187-90
86. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 2001; 49: 545-6
87. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59: 1267-72
88. Arai H, Ishiguro K, Ohno H, Moriyama H, Itoh N, Okamura N, et al. CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol 2000; 166: 201-3
89. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52
90. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001; 22: 77-8
91. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999; 270: 91-4
92. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: An ultrasensitive bienzyme-substrate-recyde enzyme-linked immunosorbent assay. Am J Pathol 2 2002; 160: 1269-78
93. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al. Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. J Neurosci Res 2001; 66: 510-6
94. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67: 2013-8
95. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090-3
96. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002; 320: 156-60
97. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology 1998; 50: 1122-7
98. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998; 13: 70-7
99. De La Monte SM, Carlson RI, Brown NV, Wands JR. Profiles of neuronal thread protein expression in Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 1038-50
100. De La Monte SM, Ghanbari K, Frey WH, Beheshti I, Averback P, Hauser SL, et al. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest 1997; 100: 3093-104
101. Blennow K, Wallin A, Chong JK. Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier. Neurodegeneration 1995; 4: 187-93
102. Parnetti L, Palumbo D, Cardinali L, Loreti F, Chionne F, Cecchetti R, et al. Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neurosci Lett 1995; 183: 43-5
103. Royds JA, Davies-Jones GA, Lewtas NA, Timperley WR, Taylor CB. Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system. J Neurol Neurosurg Psychiatry 1983; 46: 1031-6
104. Sulkava R, Viinikka L, Erkinjuntti T, Roine R. Cerebrospinal fluid neuron-specific enolase is decreased in multi-infarct dementia, but unchanged in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 549-51
105. Nooijen PT, Schoonderwaldt HC, Wevers RA, Hommes OR, Lamers KJ. Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement Geriatr Cogn Disord 1997; 8: 169-73
106. Zerr I, Bodemer M, Racker S, Grosche S, Poser S, Kretzschmar HA, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995; 345: 1609-10
107. Kropp S, Zerr I, Schulz-Schaeffer WJ, Riedemann C, Bodemer M, Laske C, et al. Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett 1999; 261: 124-6
108. Noppe M, Crols R, Andries D, Lowenthal A. Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology. Clin Chim Acta 1986; 155: 143-50
109. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 2001; 39: 409-13
110. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 1997; 235: 5-8
111. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997; 244: 566-70
112. Fukuyama R, Izumoto T, Fushiki S. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia. Eur Neurol 2001; 46: 35-8
113. Crols R, Saerens J, Noppe M, Lowenthal A. Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J Neurol 1986; 233: 157-60
114. van Gool WA, Bolhuis PA. Cerebrospinal fluid markers of Alzheimer's disease. J Am Geriatr Soc 1991; 39: 1025-39
115. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19: 109-16
116. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg 1999; 13: 56-9
117. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000; 287: 65-7
118. Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, McCormack A, Langston JW. The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci Lett 1998; 253: 13-6
119. Arai H, Higuchi S, Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease. Gerontology 1997; 43 (Suppl 1): 2-10
120. Arai H, Satoh-Nakagawa T, Higuchi M, Morikawa Y, Miura M, Kawakami H, et al. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci Lett 1998; 256: 174-6
121. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999; 259: 133-5